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Abstract
Clinical data suggest that progestins have chemopreventive properties in the development of colorectal cancer. We set out
to examine a potential protective effect of progestins and progesterone signaling on colon cancer development. In normal
and neoplastic intestinal tissue, we found that the progesterone receptor (PR) is not expressed. Expression was confined to
sporadic mesenchymal cells. To analyze the influence of systemic progesterone receptor signaling, we crossed mice that
lacked the progesterone receptor (PRKO) to the Apc
Min/+ mouse, a model for spontaneous intestinal polyposis. PRKO-Apc
Min/+
mice exhibited no change in polyp number, size or localization compared to Apc
Min/+. To examine effects of progestins on the
intestinal epithelium thatareindependent of the PR,we treated mice with MPA. Wefound no effects of either progesteroneor
MPA on gross intestinal morphology or epithelial proliferation. Also, in rats treated with MPA, injection with the carcinogen
azoxymethane did not result in a difference in the number or size of aberrant crypt foci, a surrogate end-point for adenoma
development. We conclude that expression of the progesterone receptor is limited to cells in the intestinal mesenchyme. We
did not observe any effect of progesterone receptor signaling or of progestin treatment in rodent models of intestinal
tumorigenesis.
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Introduction
The Women’s Health Initiative (WHI) was launched in 1991 to
conduct medical research into some of the major health problems of
older women. Among other studies, the WHI performed two large
prospective randomized clinical trials where postmenopausal
hormone use was evaluated. One trial consisted of treatment with
estrogens combined with the progestin medroxyprogesterone
acetate (MPA) versus placebo, to evaluate the risk of endometrial
carcinoma [1,2]. In the second trial estrogen alone was compared to
placebo in women that had previously undergone a hysterectomy
[1,3]. A substantial 40% risk reduction (P=0.003) for colon cancer
development was observed in women that received the combination
therapy[4],whereastheriskofcolorectal cancerwasslightlybutnot
significantly increased by treatment with estrogens alone.
Based on these results, progestins have been suggested as
putative chemopreventive agents for colon cancer [5,6], however,
the mechanism of action by which they work in the intestine
remains obscure.
Progesterone signaling plays multiple roles in the physiology of
the female body. Perhaps best known for its important function as
a mitogen for endometrial tissue [7] and regulator of the
mammary stem cell development [8], it also has pleiotropic effects
on many other physiological functions. For example progesterone
signaling attenuates osteogenesis [9] and increases sexual recep-
tivity [10]. Also, progesterone reduces the immune response of the
uterine environment [11], and diminishes cytokine production by
plasmacytoid dendritic cells [12,13].
All major effects of progesterone are thought to be mediated by
the progesterone receptor (PR), a member of the nuclear receptor
superfamily. This receptor, has at least two isoforms (the PR-A and
PR-B), that have distinct effects [14]. Although signaling by
progesterone is mediated by the PR exclusively [15], Progestins
(synthetic progesterone receptor ligands) can have off-target effects
at high concentrations or dosages, that are mediated by other
steroid hormone receptors such as the androgen receptor (AR), the
estradiol receptors (ER) or the glucocorticoid receptor (GR),
depending on the progestin used.
Some investigators have reported that normal colonic tissue as
well as colorectal cancers express PR mRNA [16] or show
progesterone binding capacity [17]. In contrast, work by others
suggests that few colon cancers express PR and expression is low
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epithelium [19]. PR expression has been documented in colon
cancer cell lines and data on growth inhibition of these cell lines by
progestins points towards a role for progestins as being
antiproliferative [20]. No studies comment on the function of
PR in mesenchymal cells, whereas the role of mesenchymal cells in
colon cancer is of emerging importance [21–23].
In this study we sought to elucidate the role for the progesterone
receptor and progestins in colorectal carcinoma development.
Results
The progesterone receptor is not expressed in the
epithelium of the small intestine or colon
Hypothesizing that the progesterone receptor is the main
mediator of the effect of progestins, we set out to examine the
expression of the progesterone receptor in the epithelium of the
small and large intestine (Fig. 1). Since expression of PR in
some tissues is known to vary greatly during stages of the
estrous cycle [14], we analyzed tissue of female mice in all
stages of the estrous cycle as well as male mice (data of male
mice not shown). To avoid issues of detection level and
antibody specificity, we tested multiple antibodies (see Table 1
for antibody information, data not shown), and confirmed the
results with mRNA in situ hybridization. We observed no
detectable epithelial expression of the PR at either the mRNA
or protein level (Fig. 1A–K). In contrast, some PR positivity was
observed in rare cells in the lamina propria (Fig. 1C). All
antibodies reacted with PR in the mouse uterus, which was
used as a positive control (Fig. 1E) but not with the uterus of
mice that lack the PR (PRKO mice, data not shown). To
further confirm absence of PR in normal tissue, we performed
immunoblots on lysates of mouse colon and small intestine,
using the uterus as a positive control. Both isoforms of the PR
were highly present in the uterus, but we found no expression of
the PR in both colon or small intestine (Fig. 1K).
We next analyzed PR expression in adenomas of Apc
min/+ mice.
These mice carry a mutation in the Apc gene that resembles
oncogenic mutations in patients with the Familial Adenomatous
Polyposis syndrome and in most sporadically occurring colorectal
carcinomas (Su et al., 1992). Apc
Min/+ mice develop multiple polyps
in the small and large intestine and due to their resemblance with
human colorectal adenomas, they are widely used as a model for
human colorectal cancer [24–26]. In adenomas of Apc
min/+ mice
we found that the PR was expressed by rare lamina propria cells
but not by epithelial cells (Fig. 1D).
Figure 1. Progesterone Receptor expression in mesenchymal cells in the intestine, not in the epithelium. A–E) PR
immunohistochemistry on the mouse colon (A) and small intestine (B,C) where rare cells express PR (arrowhead). And in an adenoma of an
Apc
Min/+ mouse (D). PR is widely expressed in the mouse uterus (E). F,G) In situ hybridization in mouse uterus (F) and small intestine (G). All murine
tissue shown was taken from A female animal in diestrous stage, when progesterone is high [39]. H–J) PR Expression in the human colon is located in
mesenchymal cells (I) and the smooth muscle layer (J), similar to the mouse intestine. For in situ hybridization, thick (10 mm) sections were used,
which makes identification of mesenchymal cells difficult. K) PR immunoblot on the mouse colon and small intestine. L) PR immunoblot on a panel of
colon cancer cell lines shows no expression of either PR-A or PR-B isoform. The breast cancer cell line T47D is used as a positive control.
doi:10.1371/journal.pone.0022620.g001
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colon was similar to expression we found in the mouse. In human
mucosa, PR positive cells were observed in the mesenchyme such as
leukocytes and smooth muscle cells but no epithelial expression was
detected (Fig. 1 H–J). This was the case in normal colonic
epithelium as well as adenomas and carcinomas (data not shown).
As it was previously suggested that colon cancer cells may express
PR [20], we next examined a number of different colon cancer cell
lines for expression of PR at the protein and RNA level and using
the T47D breast cancer cell line as a positive control. In a panel of 6
frequently used colon cancer cell lines, we found no evidence of PR
expression at either protein (Fig. 1L.) or RNA level (not shown)).
No effect of progesterone signaling or progestins on
intestinal epithelial proliferation or tumorigenesis
Since no PR was detectable in colon cancer cell lines, PR-
mediated signaling is not possible in these cells. At high
concentrations progestins, such as MPA that was used in the
WHI study, bind to steroid hormone receptors other than the PR
[27]. Such off-target effects might be important in the protective
role of progestins. To investigate a possible off-target effect of
MPA or progesterone directly on colonic epithelial cells, we
treated all cell lines that were previously tested negative for
expression of PR, with increasing concentrations of these steroids
(Fig. 2A). To prevent interference from steroids that are present in
high concentrations in FCS, we charcoal stripped our serum prior
to use. Additionally we used medium that was phenol red free,
since this has weak estrogenic capacities [28]. Measuring viability
of all cell lines, no effects were seen treating with concentrations up
to 200 ng ml
21, which is approximately 10 times higher than
physiological plasma levels of progesterone or than levels of MPA
that are achieved with contraceptive [29].
Even though intestinal epithelial cells may not express PR and
do not seem to be affected by progestins, these cells may be
indirectly affected by PR signaling in adjacent cells in mesen-
chyme. Also, it has been reported, that tumorigenesis can be
influenced indirectly, via systemic or central effects [30]. We
therefore decided to cross the Apc
Min/+ mouse to a PRKO
background to examine whether systemic absence of the PR
affects intestinal adenoma development in mice. Analysis of both
tumor number and size did not yield differences between PRKO
and WT mice. Also, localization of tumors throughout the
intestine and colon was not different (Fig. 3 A–C).
Although we did not observe any effect of PRKO on the
development of adenomas in the Apc
Min/+ mouse, this does not
exclude potential off-target signaling, mediated by other receptors.
Hypothesizing that progestins, such as MPA, harbor effects that
are independent from the PR, we decided to examine the effect of
daily physiological doses of MPA (4 mg kg
21) and progesterone
(32 mg kg
21) on epithelial homeostasis in the normal mouse and
the effect of MPA (1 mg kg
21) on aberrant crypt focus formation
in azoxymethane treated rats.
First, we examined if proliferation of epithelial cells was
influenced by administration of MPA or progesterone. We treated
female mice for 4 days with these hormones, and counted the
number of BrdU positive cells per crypt (Fig. 2B). No difference in
proliferation was found between animals that were treated with
MPA, progesterone or vehicle (corn oil), respectively. Also, there
were no gross changes in intestinal architecture or in differenti-
ation of distinct epithelial cell types, as could be judged on sections
of intestine of these mice, stained with Haematoxylin and Eosin.
To investigate the possibility that progestins exert their effect on
dysplastic cells rather than normal epithelium, we treated rats with
slow release pellets that contained either MPA or vehicle, and
induced colonic tumorigenesis by injecting these animals with the
Table 1. Antibodies used for immunohistochemical detection of PR.
Company Antigen Clone Raised in animal Antigen retrieval Dilution used
ABR PR MA1-410 Rabbit polyclonal Citrate 1:400
Dako PR A0098 Rabbit Polyclonal Citrate 1:400
NeoMarkers PR SP2 Rabbit Monoclonal Citrate 1:200
NeoMarkers PR AB13 Rabbit Polyclonal Citrate 1:1000
Roche BrdU BMC 9318 Mouse Monoclonal Citrate 1:200
doi:10.1371/journal.pone.0022620.t001
Figure 2. Lack of off-target effects from progestins on intestinal proliferation or development of acfs. A) Treatment of a panel of colon
cancer cell lines with MPA or progesterone (P4) has no effect on viability at relevant concentrations. B) BrdU incorporation in small intestine or colon
after challenging female animals with MPA or progesterone (P4) for four consecutive days. C–E) Acf count in the Azoxymethane treated rat shows acf
number (C), localization of acfs throughout the colon (D) and multiplicity (E) (number of crypts per acf).
doi:10.1371/journal.pone.0022620.g002
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epithelial cells, that lead to development of aberrant crypt foci
(ACFs) [31]. ACFs are hyperproliferative crypts, of which is
thought that a proportion develops into polyps and later into
carcinomas [32,33].
There was no change in the numbers of ACFs in placebo-
treated versus MPA-treated animals. Also, no effect was found on
the localization of these ACFs throughout the colon, or on the
multiplicity, (i.e. the number of crypts of which an ACF consists)
(Fig. 2C–E).
Discussion
Progestins reduced the risk of colorectal cancer in a large
randomized prospective study in postmenopausal women [2,4].
We have analyzed expression of the PR and function of the PR
and of Progestins in colorectal cancer models. We find that
although there are rare mesenchymal cells that express the PR in
the lamina propria, the PR is not expressed in either normal or
malignant intestinal epithelium or in colorectal cancer cell lines.
We do not observe any effect of either progesterone or MPA on
intestinal epithelial homeostasis or rodent models of intestinal
tumorigenesis.
The expression of the PR was previously demonstrated in whole
tissue RNA of both normal colon and colorectal cancer samples
[16,18]. Slattery and colleagues subsequently found no evidence
for PR expression in the epithelium of either normal colon or
colon cancer samples using immunohistochemistry [19]. More
recently expression of PR was described in HT29 and HCT116
colon cancer cell lines and the same authors described inhibition of
the proliferation of these cell lines by MPA.
Our findings corroborate those of Slattery and colleagues as we
find no evidence for PR expression in the epithelium of normal
small intestine or colon in humans and mice. Also, we did not
detect any PR in either human colon cancer cell lines, human
samples of colorectal cancer, in mouse adenomas or aberrant crypt
foci in the rat. Our findings suggest that the PR mRNA that was
found in whole tissue by others may have been derived from PR
positive cells present in the lamina propria or from intestinal
smooth muscle cells. Using the T47D breast cancer cell line as an
appropriate positive control for PR expression we find no evidence
of PR expression at either mRNA or protein level in any of the
colon cancer cell lines examined. In accordance with the absence
of PR expression from intestinal epithelium and colon cancer cell
lines we did not find any effect of either progesterone or MPA on
the proliferation of either normal intestinal epithelium in vivo or
colon cancer cell lines in vitro.
We were subsequently unable to find a role for progesterone
signaling in initiation or progression of intestinal adenomas in the
Apc
Min/+ mouse or on aberrant crypt formation in azoxymethane-
treated rats.
In the WHI studies it was found that the combination of MPA
plus estrogen had chemopreventive effects on colon cancer
development whereas estrogens alone had no effect. Since
treatment with MPA as a single drug has no role in postmeno-
pausal women, it was never examined. Our studies clearly show
that progesterone signaling alone does not affect rodent models of
intestinal tumorigenesis, nor were we able to find any off-target
effects of Progesterone or MPA.
Although it may be possible that the combination of estrogen
and MPA may affect colorectal cancer, this does not seem very
likely in light of the absence of PR expression in either normal
colon or colorectal cancer and lack of effect of PRKO on Apc
Min/+
adenomas. Rodent models for colorectal cancer do often not
progress to the post-adenoma stage (e.g. adenocarcinoma and
metastasis). Our studies thus can not rule out a role in late stages of
colorectal tumors for either progestin monotherapy or a
combination with estrogens.
In conclusion, our studies do not support a role for either
progesterone or MPA signaling homeostasis of normal colonic
epithelium or in colon cancer development.
Methods
Animal experiments
All experiments were performed according to the Leiden
University Medical Center animal experimental committee
guidelines. Animal experiments were approved by the animal
experimental committee (DEC) of the animal research facility
(PDC) of the Leiden University Medical Center under approval
numbers 08138 and 08145.
Wild type rats and mice were obtained from The Jackson
Laboratory (Bar Harbor, MN, USA) or from our own breeding
facility. Apc
Min animals [34] were obtained via The Jackson
Laboratory. PRKO mice [35] were bred heterozygously into
Apc
Min/+ males. Male animals that were heterozygous for both
alleles were bred into females, heterozygous for the PRKO allele
to generate females that were PRKO Apc
Min/+.
For the Rat azoxymethane experiment five week old rats were
ovariectomized and slow release pellets with MPA or vehicle
(Innovative Research of America, Sarasota, FL, USA) were
implanted subcutaneously in the neck. These pellets contained
25 mg of MPA in a 90 day slow release pellet. Vehicle pellets
were of the same size and composition, but contained no
steroids. After surgery and implantation of the pellet, rats were
left to acclimatize for one week prior to injection with
azoxymethane.
Subsequently, rats were injected twice with azoxymethane
(10 mg kg
21 day
21; Sigma-Aldrich, Zwijndrecht, Netherlands)
with 7 days between the two injections. Six weeks after the first
injection, animals were sacrificed and colons were fixed.
To assess proliferation in vivo, BrdU incorporation studies were
performed. Six weeks old mice were injected on four consecutive
days MPA (Sigma-Aldrich), Progesterone (Sigma-Aldrich) or
vehicle (10 animals per group). Hormones were dissolved in
DMSO which was subsequently diluted to 10% in corn oil. All
volumes were equivalent. One hour prior to sacrifice, all animals
were injected with 200 ml BrdU (10 mg ml
21 in PBS; Sigma-
Aldrich).
Hormone treatment
For rat studies, the MPA dosage used was based on the IC50 of
ovulation-inhibition in rats (0,1 mg kg
21 day
21) [36], to guarantee
physiologically active concentrations, this concentration was
multiplied tenfold (1 mg kg
21 day
21). Rats received a 90 day
slow release pellet to ensure stable release. This was approximated
by placement of a pellet containing 25 mg of MPA (1,1 mg kg
21
day
21).
Figure 3. The Progesterone receptor has no influence on intestinal polyposis. A–C) Development of spontaneous polyposis in the Apc
Min/+
mouse is not altered by PRKO (10 female animals per genotype).
doi:10.1371/journal.pone.0022620.g003
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MPA was multiplied by 4 to ensure allosteric conversion between
rats and mice [37]. The concentration of progesterone was based
on the report of Yamanouchi et al. [38], where estrogen induced
proliferation in rats was inhibited by treatment with 8 mg kg
21
day
21 progesterone. Allosteric conversion resulted in treatment
with 32 mg kg
21 day
21 progesterone in mice.
Tissue processing, Immunohistochemistry and In situ
hybridization
Tissue was fixed in 10% ice-cold formalin embedded in
paraffin. Sections of 4 mm were deparaffinized in xylene and
rehydrated.
For immunohistochemistry, endogenous peroxidase was
blocked using 0.3% H2O2 in Methanol. The sections were cooked
in 0.01 M Citrate buffer pH 6.0 for 20 minutes and incubated
with the primary antibody in PBS with 1% BSA and 0.1% Triton
X-100.
Antibody binding was visualized with Powervision HRP labeled
secondary antibodies, and diaminobenzidine for substrate devel-
opment. All sections were counterstained with Mayer’s haema-
toxylin. For a list of all antibodies used, see Table 1. Immuno-
histochemistry in figures was done with the rabbit monoclonal
antibody from Neomarkers (clone SP2), since the background was
low using this antibody.
For in situ hybridizations, sections were deparaffinized and
rehydrated. Subsequently, sections were incubated in 1 M HCl for
10 minutes, treated with proteinase K in PBS for 20 minutes, and
refixed with 4% paraformaldehyde for 10 minutes. Sections were
acetylated with acetic anhydride, and incubated with a digox-
igenin (DIG)-labeled probe over three nights at 68uC. After three
stringency washes with 50% formamide in SSC buffer (pH 4.5) at
65uC, sections were incubated with alkaline phosphatase-labeled
anti-DIG Fab fragments (Roche). Probe binding was visualized
using the NBT-BciP substrate (Sigma-Aldrich).
BrdU and aberrant crypt focus (acf) counting
For BrdU incorporation studies, sections were stained as
described above. Blinded to treatment group, the number of
BrdU
+ cells was counted in at least 30 crypts in each animal
(n=10 per group).
For counting of aberrant crypt foci (as), fixed colons were
stained with 1% methylene blue (Sigma-Aldrich) in PBS and
washed in fresh PBS. Acf number and multiplicity was evaluated
in the entire colon under a dissection microscope.
Immunoblotting
Cells and tissue were lysed in cell lysis buffer (Cell Signaling
Technology, Leiden, Netherlands). Protein concentration in
lysates was assessed by bicinchoninic acid protein assay reagent
(Pierce, Thermo scientific, Etten-Leur, Netherlands). Lysates were
boiled in sample buffer containing 0.25 M Tris-HCl pH 6.8, 8%
SDS, 30% glycerol, 0.02% bromophenol blue and 1% b-ME.
Separation was done on 10% SDS-PAGE, and proteins were
transferred to a PVDF membrane. Specific detection was done by
incubating the blot overnight in TBS with 0.1% Tween-20 with
1% BSA with anti-PR (NeoMarkers 1:500) and anti-Actin (1:2000;
Santa Cruz Biotechnology, CA, USA) antibodies. Antibody
binding was visualized using the Lumi-Light western blotting
substrate (Roche).
Charcoal stripping of fetal calf serum
Five grams of charcoal (Merck) was put into 50 ml of FCS and
left overnight on a rollerbank at 4uC. The charcoal was pelletted
by spinning at 5000 rpm subsequently and the serum was
decantated and filtered through a 0,22 m filter.
Cell Culture and MTT
Cells culture was maintained in DMEM, supplemented with
10% FCS and 1% penicillin and streptomycin. For the MTT
assay, cells were plated onto 96 well plates in phenol red free
DMEM F12, supplemented with 5% Charcoal stripped FCS and
1% penicillin and streptomycin. Cells were left to adhere
overnight. Per condition, 10 wells with cells were treated with
the indicated concentration of either MPA or Progesterone
(Sigma-Aldrich), dissolved in 100% ethanol. In all conditions, a
final concentration of 1% ethanol was maintained. After 48 hours
of treatment, thiazolyl blue tetrazolium blue (MTT) substrate
(Sigma-Aldrich) was added to each well (5 mg ml
21 end
concentration), and incubated for 4 hours. Culture medium
containing excess MTT was taken off, and cells were lysed in
isopropanol. MTT was measured colorimetrically at 570 nm. The
average of all 10 wells per condition was taken as the outcome of
one experiment.
Concentrations used in in vitro studies were based on reported
medical reference values: in healthy cycling females, progesterone
concentrations range from 1–20 ng ml
21. Progesterone plasma
concentration is maximally 90 nanomole l
21 (approximately
30 ng ml
21) in healthy females. MPA plasma concentrations, 5–
20 days after injection of a standard contraceptive dose (consisting
of an intramuscular injection of 150 mg MPA) ranges from 10 to
25 ng ml
21 [29].
Statistical analysis
All data are presented as mean 6 standard error of the mean.
Cell culture experiments were repeated at least three independent
times. Statistical analysis of cell culture experiments was performed
by 2-way ANOVAs analysis.
For animal experiments, student T-Test or 1-way ANOVAs
tests were used. In sub analysis of localization or size, 2-way Anova
tests were used. All Anova tests were followed by Bonferroni’s post
test for multiple comparisons.
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